BPMC logo

Blueprint Medicines (BPMC)

Profile

Full Name

Blueprint Medicines Corporation

Ticker Symbol

BPMC

Exchange

NASDAQ

Country

United States

IPO

April 30, 2015

Indexes

Not included

Employees

649

Key Details

Price

$87.53

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$508.82M(+104.04% YoY)

Annual EPS

-$1.07(+87.22% YoY)

Next earnings date

May 2, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Mar 17, 25 Jefferies
Buy
Mar 7, 25 Scotiabank
Sector Outperform
Mar 3, 25 Citizens Capital Markets
Market Outperform
Feb 14, 25 Needham
Buy
Feb 14, 25 JMP Securities
Market Outperform
Feb 14, 25 HC Wainwright & Co.
Buy
Feb 13, 25 Needham
Buy
Feb 4, 25 JP Morgan
Overweight
Jan 27, 25 Piper Sandler
Neutral
Jan 15, 25 JMP Securities
Market Outperform

Institutional Ownership

  • What is the ticker symbol for Blueprint Medicines?
  • Does Blueprint Medicines pay dividends?
  • What sector is Blueprint Medicines in?
  • What industry is Blueprint Medicines in?
  • What country is Blueprint Medicines based in?
  • When did Blueprint Medicines go public?
  • Is Blueprint Medicines in the S&P 500?
  • Is Blueprint Medicines in the NASDAQ 100?
  • Is Blueprint Medicines in the Dow Jones?
  • When was Blueprint Medicines's last earnings report?
  • When does Blueprint Medicines report earnings?
  • Should I buy Blueprint Medicines stock now?

What is the ticker symbol for Blueprint Medicines?

The ticker symbol for Blueprint Medicines is NASDAQ:BPMC

Does Blueprint Medicines pay dividends?

No, Blueprint Medicines does not pay dividends

What sector is Blueprint Medicines in?

Blueprint Medicines is in the Healthcare sector

What industry is Blueprint Medicines in?

Blueprint Medicines is in the Biotechnology industry

What country is Blueprint Medicines based in?

Blueprint Medicines is headquartered in United States

When did Blueprint Medicines go public?

Blueprint Medicines's initial public offering (IPO) was on April 30, 2015

Is Blueprint Medicines in the S&P 500?

No, Blueprint Medicines is not included in the S&P 500 index

Is Blueprint Medicines in the NASDAQ 100?

No, Blueprint Medicines is not included in the NASDAQ 100 index

Is Blueprint Medicines in the Dow Jones?

No, Blueprint Medicines is not included in the Dow Jones index

When was Blueprint Medicines's last earnings report?

Blueprint Medicines's most recent earnings report was on Feb 13, 2025

When does Blueprint Medicines report earnings?

The next expected earnings date for Blueprint Medicines is May 2, 2025

Should I buy Blueprint Medicines stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page